{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Chloroquine+diphosphate", "query": { "intervention": "Chloroquine diphosphate" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 198, "total_pages": 20, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Chloroquine+diphosphate&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-04T07:59:55.500Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02451748", "title": "IL-7 and IL-7R Expression in RA Patients With Active vs. Inactive Disease Treated With DMARD or CIMZIA", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "Lab Work", "type": "OTHER" }, { "name": "Certolizumab pegol (CDP870, tradename Cimzia)(prefilled syringes at the dose of 200mg)", "type": "DRUG" }, { "name": "Certolizumab pegol (CDP870, tradename Cimzia)", "type": "DRUG" }, { "name": "Hydroxychloroquine", "type": "DRUG" }, { "name": "Sulfasalazine", "type": "DRUG" }, { "name": "Medrol", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Triamcinolone", "type": "DRUG" }, { "name": "Naproxen", "type": "DRUG" }, { "name": "Leflunomide", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "humira", "type": "DRUG" } ], "intervention_types": [ "OTHER", "DRUG" ], "sponsor": "University of Illinois at Chicago", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 32, "start_date": "2015-08", "completion_date": "2017-12", "has_results": true, "last_update_posted_date": "2024-07-10", "last_synced_at": "2026-09-04T07:59:55.500Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT02451748" }, { "nct_id": "NCT00531817", "title": "A Study of Tocilizumab in Combination With DMARDs in Patients With Moderate to Severe Rheumatoid Arthritis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "Tocilizumab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Permitted DMARDs", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 619, "start_date": "2007-10", "completion_date": "2011-03", "has_results": true, "last_update_posted_date": "2012-08-20", "last_synced_at": "2026-09-04T07:59:55.500Z", "location_count": 156, "location_summary": "Birmingham, Alabama • Montgomery, Alabama • Lake Havasu City, Arizona + 135 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Montgomery", "state": "Alabama" }, { "city": "Lake Havasu City", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT00531817" }, { "nct_id": "NCT05630989", "title": "A Registry to Capture Patient Outcomes With KRAS G12R Altered Advanced Pancreatic Ductal Adenocarcinoma Treated With MEK Inhibitor-based Combination Therapy", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Pancreatic Ductal Adenocarcinoma" ], "interventions": [ { "name": "combination therapy with no MEKi", "type": "OTHER" }, { "name": "combination therapy with MEKi-HCQ", "type": "DRUG" }, { "name": "combination therapy with MEKi-EGFRi", "type": "DRUG" }, { "name": "combination therapy with MEKi.", "type": "DRUG" } ], "intervention_types": [ "OTHER", "DRUG" ], "sponsor": "Mandana Kamgar, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 80, "start_date": "2023-02-07", "completion_date": "2027-08-01", "has_results": false, "last_update_posted_date": "2026-05-05", "last_synced_at": "2026-09-04T07:59:55.500Z", "location_count": 1, "location_summary": "Milwaukee, Wisconsin", "locations": [ { "city": "Milwaukee", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT05630989" }, { "nct_id": "NCT04787991", "title": "Exploratory Platform Trial to Evaluate Immunotherapy Combinations With Chemotherapy for the Treatment of Patients With Previously Untreated Metastatic Pancreatic Adenocarcinoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Pancreatic Adenocarcinoma" ], "interventions": [ { "name": "Nivolumab (Cohort A)", "type": "DRUG" }, { "name": "Ipilimumab (Cohort A, B and C)", "type": "DRUG" }, { "name": "Hydroxychloroquine (HCQ) (Cohort B)", "type": "DRUG" }, { "name": "Nab-paclitaxel (nP) (Cohort A, B and C)", "type": "DRUG" }, { "name": "Gemcitabine (gem) (Cohort A, B and C)", "type": "DRUG" }, { "name": "NG350A (Cohort C)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Cancer Insight, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 45, "start_date": "2021-08-09", "completion_date": "2025-07-31", "has_results": false, "last_update_posted_date": "2025-10-30", "last_synced_at": "2026-09-04T07:59:55.500Z", "location_count": 6, "location_summary": "Los Angeles, California • San Francisco, California • Stanford, California + 3 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "New York", "state": "New York" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT04787991" }, { "nct_id": "NCT04464759", "title": "A Study of Nivolumab and Hydroxychloroquine or Nivolumab/Ipilimumab and Hydroxychloroquine in Advanced Melanoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Melanoma" ], "interventions": [ { "name": "Nivolumab", "type": "DRUG" }, { "name": "Hydroxychloroquine", "type": "DRUG" }, { "name": "Ipilimumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ravi Amaravadi, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 41, "start_date": "2020-10-21", "completion_date": "2027-05-12", "has_results": false, "last_update_posted_date": "2026-06-16", "last_synced_at": "2026-09-04T07:59:55.500Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT04464759" }, { "nct_id": "NCT02057250", "title": "To Evaluate Sarilumab - SAR153191 (REGN88) - Auto-injector Device In Patients With Rheumatoid Arthritis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "RA" ], "interventions": [ { "name": "Sarilumab", "type": "DRUG" }, { "name": "Auto-Injector Device (AID)", "type": "DEVICE" }, { "name": "Pre-filled Syringe (PFS)", "type": "DEVICE" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Sulfasalazine", "type": "DRUG" }, { "name": "Leflunomide", "type": "DRUG" }, { "name": "Hydroxychloroquine", "type": "DRUG" } ], "intervention_types": [ "DRUG", "DEVICE" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 217, "start_date": "2014-03", "completion_date": "2016-03", "has_results": true, "last_update_posted_date": "2017-06-20", "last_synced_at": "2026-09-04T07:59:55.500Z", "location_count": 31, "location_summary": "Huntsville, Alabama • Peoria, Arizona • Roseville, California + 25 more", "locations": [ { "city": "Huntsville", "state": "Alabama" }, { "city": "Peoria", "state": "Arizona" }, { "city": "Roseville", "state": "California" }, { "city": "Boulder", "state": "Colorado" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02057250" }, { "nct_id": "NCT00844207", "title": "A Phase 1 Study To Estimate The Relative Bioavailability Of Fixed Combination Tablets Of Azithromycin And Chloroquine Compared To Co-Administered Individual Tablets Of Azithromycin And Chloroquine", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Malaria" ], "interventions": [ { "name": "Fixed combination of Azithromycin and Chloroquine", "type": "DRUG" }, { "name": "Azithromycin and Chloroquine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 40, "start_date": "2009-02", "completion_date": "2009-04", "has_results": false, "last_update_posted_date": "2009-04-21", "last_synced_at": "2026-09-04T07:59:55.500Z", "location_count": 1, "location_summary": "New Haven, Connecticut", "locations": [ { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT00844207" }, { "nct_id": "NCT00455325", "title": "Chloroquine to Treat People With Metabolic Syndrome Aim2 (ARCH-MS)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metabolic Syndrome X", "Overweight", "Hypertension", "Dyslipidemias", "Prediabetic State" ], "interventions": [ { "name": "Placebo Comparator: First Intervention (3 weeks)", "type": "DRUG" }, { "name": "Active Comparator: Second Intervention (3 weeks)", "type": "DRUG" }, { "name": "Active Comparator: Third Intervention (3 weeks)", "type": "DRUG" }, { "name": "Active Comparator: Fourth Intervention (3 weeks)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 35, "start_date": "2004-09", "completion_date": "2012-03", "has_results": true, "last_update_posted_date": "2022-05-10", "last_synced_at": "2026-09-04T07:59:55.500Z", "location_count": 1, "location_summary": "St Louis, Missouri", "locations": [ { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT00455325" }, { "nct_id": "NCT01480154", "title": "Akt Inhibitor MK2206 and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors, Melanoma, Prostate or Kidney Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Malignant Solid Neoplasm", "Stage III Cutaneous Melanoma AJCC v7", "Stage III Prostate Cancer AJCC v7", "Stage III Renal Cell Cancer AJCC v7", "Stage IIIA Cutaneous Melanoma AJCC v7", "Stage IIIB Cutaneous Melanoma AJCC v7", "Stage IIIC Cutaneous Melanoma AJCC v7", "Stage IV Cutaneous Melanoma AJCC v6 and v7", "Stage IV Prostate Cancer AJCC v7", "Stage IV Renal Cell Cancer AJCC v7" ], "interventions": [ { "name": "Akt Inhibitor MK2206", "type": "DRUG" }, { "name": "Hydroxychloroquine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 62, "start_date": "2011-11-23", "completion_date": "2027-03-31", "has_results": false, "last_update_posted_date": "2026-04-13", "last_synced_at": "2026-09-04T07:59:55.500Z", "location_count": 1, "location_summary": "New Brunswick, New Jersey", "locations": [ { "city": "New Brunswick", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT01480154" }, { "nct_id": "NCT04349410", "title": "The Fleming [FMTVDM] Directed CoVid-19 Treatment Protocol", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "CoVid 19 Positive" ], "interventions": [ { "name": "Hydroxychloroquine, Azithromycin", "type": "DRUG" }, { "name": "Hydroxychloroquine, Doxycycline", "type": "DRUG" }, { "name": "Hydroxychloroquine, Clindamycin", "type": "DRUG" }, { "name": "Hydroxychloroquine, Clindamycin, Primaquine - low dose.", "type": "DRUG" }, { "name": "Hydroxychloroquine, Clindamycin, Primaquine - high dose.", "type": "DRUG" }, { "name": "Remdesivir", "type": "DRUG" }, { "name": "Tocilizumab", "type": "DRUG" }, { "name": "Methylprednisolone", "type": "DRUG" }, { "name": "Interferon-Alpha2B", "type": "DRUG" }, { "name": "Losartan", "type": "DRUG" }, { "name": "Convalescent Serum", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "The Camelot Foundation", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 1800, "start_date": "2020-04-11", "completion_date": "2020-09-14", "has_results": false, "last_update_posted_date": "2020-11-12", "last_synced_at": "2026-09-04T07:59:55.500Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04349410" } ] }